Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.

Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ.

J Immunother. 2008 Jan;31(1):72-80.

PMID:
18157014
2.

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ.

J Clin Oncol. 2007 Mar 1;25(7):876-83.

PMID:
17327609
3.

Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.

Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM.

Clin Cancer Res. 2006 Aug 1;12(15):4645-51.

4.

Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies.

Fishman MN, Garrett CR, Simon GR, Chiappori AA, Lush RM, Dinwoodie WR, Mahany JJ, Dellaportas AM, Cantor A, Gollerki A, Cohen MB, Sullivan DM.

Clin Cancer Res. 2006 Jan 15;12(2):523-8.

5.

The absolute bioavailability of oral vinorelbine in patients with solid tumors.

Lush RM, McCune JS, Tetteh L, Thompson JA, Mahany JJ, Garland L, Suttle AB, Sullivan DM.

Cancer Chemother Pharmacol. 2005 Dec;56(6):578-84. Epub 2005 Jul 7.

PMID:
16001165
6.

Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies.

Garrett CR, Fishman MN, Rago RR, Williams CC, Dellaportas AM, Mahany JJ, Lush RM, Dalton WS, Gollerkeri A, Cohen MB, Sullivan DM.

Clin Cancer Res. 2005 May 1;11(9):3335-41.

7.

A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors.

Moulder SL, Mahany JJ, Lush R, Rocha-Lima C, Langevin M, Ferrante KJ, Bartkowski LM, Kajiji SM, Noe DA, Paillet S, Sullivan DM.

Clin Cancer Res. 2004 Nov 1;10(21):7127-35.

8.

Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature.

D'Amato G, Rocha Lima C, Mahany JJ, Muro-Cacho C, Haura EB.

Lung Cancer. 2004 Jun;44(3):381-90. Review.

PMID:
15140552
9.

Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma.

Antonia SJ, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo MJ, Friberg M, Alsarraj M, Mahany JJ, Pow-Sang J, Cantor A, Janssen W.

J Urol. 2002 May;167(5):1995-2000.

PMID:
11956426

Supplemental Content

Loading ...
Support Center